|Felipe Albrecht, PhD||Roche|
Bioinformatics and Computer Scientist, Pharma Research and Early Development (pRED)
Felipe Albrecht has a Bachelor, Masters, and PhD degree in Computer Science, but his projects were always related to molecular biology. During his PhD he was involved with Computational Epigenetics, working in word-wide projects. After his PhD he joined Roche in Germany. Where he first worked in the Mass Spectrometry department in the Large Molecule Research and Development, developing laboratory automation and data handling solutions. Currently, he is working in the Computational Engineering and Data Science department, where he is working with NGS data and providing bioinformatics solutions for the Large Molecules Discovery department. Felipe has extensive experience in software development as a developer to architect and project leader. He has experience in different programming languages, from C++ to Python, passing through TypeScript. Also, in different environments, such as Linux and Mac OS, and had developed tools using distributed computing. Currently, he is focusing on developing tools for support biological and pharmaceutical tasks using cloud computing.
|Brandon Allgood, PhD||Integral|
Brandon Allgood, PhD, is the VP, Head of Technology and Innovation at Integral Health. Prior to this Brandon was the CTO and cofounder at Numerate, Inc, an AI driven drug discovery company, which was acquired by Integral Health in September of 2019. At Numerate Brandon lead research and development of Numerate’s AI platform. He also led the data science group, was the primary technical lead on both internal and collaborative drug discovery programs and was responsible for the technology vision at Numerate. Prior to becoming CTO at Numerate Brandon also served as Director of Computational Science at Numerate and as a Research Scientist at Pharmix. He received a BS in Physics from the University of Washington, Seattle, and a PhD in Computational Physics from the University of California, Santa Cruz. Brandon has authored scientific publications in astrophysics, solid-state physics, and computational chemistry and biology and has 18 years of experience in AI, mathematical modeling, and large-scale cloud and distributed computing. He advises a number of venture capital firms and start-up companies, is a cofounder of the Alliance for AI in Healthcare, a member of the Forbes Technology Council and a University of California, Santa Cruz Foundation Trustee.
|Mohammed AlQuraishi, PhD||Harvard Medical School|
Systems Biology Fellow
I am an Independent Fellow in Systems Pharmacology at Harvard Medical School. Prior to joining Harvard, I completed my PhD in Genetics from Stanford University in the labs of Harley McAdams and Lucy Shapiro. Prior to that still, I worked at Wolfram Research developing computational biology functionality for Mathematica, and founded several startups in the software and mobile space. My research interests lie at the intersection of structural and systems biology.
|Rachana Ananthakrishnan||Globus, University of Chicago|
Rachana Ananthakrishnan is a Product Manager at the Computation Institute in the University of Chicago, and has a Staff Appointment at Argonne National Laboratory. Rachana works for the Globus project, designing and building secure data management solutions for researchers across domains, and help shape the services and offerings of the team. She has worked on security and data management solutions on various projects including Earth System Grid, Biomedical Informatics Research Network (BIRN) and XSEDE. Prior to this, she worked on the Globus Toolkit engineering team, leading the efforts in web services and security technologies. Rachana received her MS in Computer Science at Indiana University, Bloomington.
|Chris Anderson||Clinical OMICs|
No bio available
|Gustavo Arango, PhD||AstraZeneca|
Senior Data Scientist – Oncology Bioinformatics
Gustavo Arango is a PhD in computer science, Masters and Undergrad in Electrical Engineering who has been working in diverse areas through his scientific career, including: digital signal processing, web development, machine learning, bioinformatics, natural language processing and deep learning. Currently, he is working in the oncology bioinformatics team at AstraZeneca where he is applying deep neural networks to learn patterns from genomics data. Prior, he received his PhD (2019) from the department of Computer Science at Virginia Tech, where he developed bioinformatics tools to process metagenomics data. Particularly, by using machine learning and deep learning to leverage accurate predictions of antibiotic resistance genes from second and third generation sequencing technologies.
|Abel Archundia||Bayer Pharma AG|
Global Head, IT & Digital Transformation
Abel joined Bayer July 2017, as head of IT and Digital Transformation for Bayer Pharma, and member of Bayer Group IT Board. Before joining Bayer, Abel was Global CIO, Sandoz Division (Generics, 2012-) as well as head of IT for Novartis Technical Operations (~85 plants) looking after manufacturing, supply chain and quality (2015-) and member of the Novartis IT and Business Services Board. Past positions include Cemex (CIO Europe-Asia from Madrid), Dell (General Manager, Mexico, and Supply Chain, Latin America) and Boston Consulting Group (Principal, Monterrey and Dallas offices). He holds a degree in electronics engineering from Tec de Monterrey, Mexico, and an MBA and Public Management degree from Stanford Graduate School of Business. Abel is married and has two children, young men who keep him on his toes. He enjoys sports like competitive rowing and swimming, loves the outdoors and is a lousy golfer.
CEO and Co-Founder
Ardy Arianpour is CEO & Co-Founder of Seqster, an award-winning SaaS healthcare platform that enables organizations to drive efficient healthcare via comprehensive medical records (EHR), individual genomic profiles (DNA), and personal health device data. For the first time, users create their own matched, longitudinal health data profile across all of their US-based healthcare data sources through person-centric interoperability. Ardy is a visionary health tech executive and serial entrepreneur in biotech and digital health. Prior to starting Seqster, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics, and SVP of Ambry Genetics that sold to Konica for $1B in 2017. As a key player in the 2013 landmark SCOTUS decision scrapping gene patents, Ardy played an instrumental role in expanding genetic testing access with the launch of BRCA testing benefiting patients and family members across the country. Ardy received his BS in Biological Sciences from UC Irvine and an MBA from Marshall Goldsmith School of Management. 2019 Recipient of Top 40 Healthcare Transformer and SDBJ 40 under 40.
|Timothy Aungst, PharmD||MCPHS University|
Associate Professor, Pharmacy Practice
Timothy Aungst, PharmD is an Associate Professor of Pharmacy Practice at MCPHS University, Worcester, MA. He is passionate about the role of digital health in patient care. His first pursuits in the field was writing for multiple companies on mHealth and Digital Health, with a focus on mobile apps for patient utilization and recommendation for prescribing my providers. Since then, he has conducted research on digital health technologies in the pharmacy space and published in multiple peer review journals and spoken at multiple venues on the topic. He hopes to inspire the pharmacy profession to further integrate digital health into patient care and raise awareness on the future possibilities posed in the coming decades.
|J Christian Baber, PhD||Takeda|
Head, Scientific Informatics
No bio available
|Rebecca Baker, PhD||National Institutes of Health|
Director, HEAL (Helping to End Addiction Long-term) Initiative, Office of the Director
Rebecca G. Baker, PhD, is the director of the Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, in the Office of the Director, NIH. Dr. Baker leads coordination of NIH HEAL Initiative programmatic activities between the Office of the Director and relevant Institutes and Centers (ICs). She manages the Office of the NIH HEAL Initiative, including NIH HEAL Initiative staff, and oversees management of NIH HEAL Initiative governance committees. Dr. Baker helped develop the NIH HEAL Initiative, working closely with NIH and IC leadership. She also provides expert advice to and represents the NIH Director on initiative-related activities, including interagency efforts in pain and opioid research and policy. Prior to holding this position, Dr. Baker was special assistant to the NIH Director and the Principal Deputy Director working directly with NIH leadership to analyze complex biomedical research policy issues and assist in the development of new science and policy initiatives. Before that, she worked in the NIH Office of Science, Outreach, and Policy, where she worked on legislative, communications, and policy issues. Dr. Baker also worked in the NIH Office of Science Policy, where she contributed to the development and implementation of the NIH Genomic Data Sharing Policy. Previously, she worked as a postdoctoral scientist using next-generation DNA sequencing to identify novel disease-causing genes in patients with rare immunological diseases. She earned her PhD from the University of Pennsylvania and her bachelor's degree from Cornell University.
|Dorothee Bartels, PhD||X The Moonshot Factory|
Clinical and Real World Data Strategy Lead
Dorothee B. Bartels is Clinical and Real World Data Strategy Lead at X, Alphabet. She used to be Corporate Head of Global Epidemiology at Boehringer Ingelheim (BI) for 10 years and for nearly two years Chief Digital Science Officer in the digital incubator of BI. She holds a Professorship of Epidemiology and Public Health at Hannover Medical School and is Adjunct Professor at McGill University, where she lectures in the course of Advanced Pharmacoepidemiology. Her research is focused on secondary data use and data linkages, on innovative real world data analysis approaches, new strategies for faster drug developments and approvals, and digital epidemiology, in particular combining AI/ML and traditional epidemiological methods
|L Michelle Bennett, PhDfsyvdcqwdycvduztwwxqtcbqceraazbrffax||National Cancer Institute|
Director, Center for Research Strategy
Dr. Bennett directs NCI’s Center for Research Strategy, a science-based office that since 2015 collaboratively develops recommendations for addressing scientific opportunities, monitors the direction and application of scientific knowledge and resources, and identifies research funding gaps. Prior to taking on this role, she served as the deputy scientific director of the Division of Intramural Research at the National Heart, Lung, and Blood Institute and before that was deputy director at NCI’s Center for Cancer Research. Dr. Bennett earned her PhD in oncology from the University of Wisconsin–Madison studying genetic susceptibility to cancer and, as a postdoctoral fellow at the National Institute of Environmental Health Sciences, performed some of the earliest work on BRCA1 and BRCA2 including the characterization and localization of BRCA1 to the long arm of Chromosome 17. Dr. Bennett has extensive practical experience in promoting collaboration and team-based approaches by bringing together research scientists with diverse backgrounds and expertise to solve complex scientific problems. She has supported efforts to increase diversity in the biomedical workforce, played a leadership role in launching and building the NIH Stadtman Tenure Track Investigator program, and developed a trans-NIH web presence for the NIH Intramural program. Dr. Bennett is the recipient of many awards, including NIH and Institute Director’s Awards, the NCI Women’s Scientist Advisors Achievement Award, and the NCI Exceptional Mentor Award.
|Dennis Bergau, PhD||AbbVie|
Senior Research Pharmacologist & Operations Lead Cardiac Safety
Dr. Dennis M. Bergau received a Bachelor of Science in Biology from Northeastern University in Boston, which included a work study program at the Harvard School of Public Health in the Bernard Lown Cardiovascular Laboratories. Before, during, and after his Physiology Master of Arts Degree work at Boston University, he spent 10 years working in the departments of Cardiology and Cardiovascular Surgery at Children's Hospital-Boston doing pre-clinical and clinical research. Upon completion of his MA efforts, he was a programmer for 10 years at Hewitt Associates, a Human Resources consulting firm. Dr. Bergau joined Abbott Laboratories in 2007 where he grew an internally-developed Machine Learning system into a functional area, making Abbott, part of which later became Abbvie, one of only two large pharma companies in the industry to have their own internal ECG core lab with worldwide ECG processing capabilities. His efforts have contributed to 8 successful regulatory approvals. While working full time at Abbott/Abbvie, he earned a PhD in Biomedical Engineering with a focus in Bioinformatics from the University of Illinois at Chicago. Dr. Bergau has recently collaborated with Medical Affairs and Key Opinion Leaders to develop and present international seminar content for the clinical applicability of AI in the treatment of Rheumatoid Arthritis, he is currently developing a framework to evaluate drug efficacy on apoptotic pathways in oncology, and contributing to the expansion of internal automated ECG analysis capabilities to identify novel electrophysiological biomarkers.
Director, Translational Research Business Technologies
Jay Bergeron is Director, Digital Client Partner for Early Clinic Development and Integrative Biology at Pfizer. He served as the Scientific Coordinator of IMI-eTRIKS, a $30M Public Private Partnership for building open source translation research information management systems.
|Devipsita Bhattacharya, PhD||SUNY Albany|
Assistant Professor, Information Security & Digital Forensics
Devi Bhattacharya is an Assistant Professor in the Department of Information Security and Digital Forensics at the University at Albany, SUNY. She holds a doctorate in Management Information Systems (MIS) from the University of Arizona. Her research interests include online news propagation, large scale network analysis, and information security and performance analysis of distributed computing systems.
|Govinda Bhisetti, PhD||Biogen|
Principal Investigator and Head of Computational Chemistry
Govinda Bhisetti is a Principal Investigator and Head of Computational Chemistry department at Biogen. His joined Biogen in 2014. Govinda got his Ph. D. from Indian Institute of Science, Bangalore in 1986. He moved to Scripps Research Institute, La Jolla, CA in 1987 to do to post-doctoral research. His work at Scripps involved use of Cray XMP supercomputer to simulate protein-ligand interactions and design novel inhibitors. From there, he went to work at Vertex Pharmaceuticals Inc. in 1990 and worked in the Computational Sciences department for 22+ years where he led molecular modeling and drug design efforts on several drug discovery projects. His research at Vertex led to the discovery of three FDA approved drugs: two AIDS drugs, Agenerase (amprenavir) and Lexiva (fosamprenavir), and one Hepatitis C drug, Incivek (Telaprevir). He is a co-inventor of these drugs and named inventor on 26 patents. He published 72 research papers including review articles and book chapters. His current activities include application of state of the art computational methods in the discovery of novel drugs for neurodegenerative and neuroinflammatory diseases.
|Brian Bissett||IEEE USA|
Jeff founded Bioinformatics.org in 1998 and co-founded Scilico, LLC in 2015. He received his MSc in Chemistry & Biochemistry from Boston College in 1999. At Bioinformatics.org, Jeff created its career-advancement resources, including those for training and employment. By working together with Martin to create Scilancer, Jeff is continuing to help people pursue careers in the scientific and technological fields.
|Celeste Blackman||Green Zone Culture Grp|
Celeste Blackman, co-founder of the Green Zone Culture Group and the Radical Collaboration for Women Program.
Celeste has over 20 years of experience building positive, high-trust work environments that energize and engage the human spirit. She helps leaders, managers and teams reduce their defensive behaviors so they can work better together! The results: greater levels of accountability, higher productivity, more enthusiastic engagement, deeper levels of trust and respect, and more creative and collaborative problem solving.
Celeste has worked with a wide range of clients including: NASA, the Natioanl Cancer Institute, Goodyear, Business Consultants of Japan, Siemens, The Department of Defense, and Vanderlande Industries.
|Vivien Bonazzi, PhD||Deloitte Consulting LLP|
Chief Biomedical Data Scientist, Managing Director
Vivien Bonazzi, PhD, recently joined its government and public services practice as both a managing director and its chief biomedical data scientist for Deloitte Consulting LLP. In this position, Bonazzi will focus on helping federal agencies utilize data science methods, technologies and cyberinfrastructures to better understand and utilize biomedical data. Previously, Bonazzi was a senior advisor in the Office of the Director at National Institutes of Health (NIH) as well as co-founder and leader of the NIH Data Commons. In her role, she focused on creating connections across all NIH institutes, other government agencies, nonprofit, and commercial organizations in the U.S. and internationally to create new ways to share, access, analyze, find and provide attribution to biomedical data and tools regardless of geographical location, size, or complexity of Prior to NIH, Bonazzi held several roles in the private and nonprofit sector, including Bonazzi holds a Bachelor of Science degree from the University of Canberra, Australia, and a master's degree and doctorate in biomedicine and computational biology from the University of Melbourne, Australia.
|Edward Bowen, PhD||GlaxoSmithKline|
Vice President, AI & Machine Learning
Ed Bowen is Vice President, AI & Machine Learning in R&D at GlaxoSmithKline (GSK). He leads a team of machine learning engineers using AI as a technology multiplier for GSK’s R&D strategy, enabling the discovery and development of transformational treatments for patients. His team delivers models and solutions across a wide range of medicines discovery problems including Target validation, enhanced clinical trial design, medicines scale-up, medicines portfolio optimization, protein engineering, and molecular design. Ed participate or leads a number of industry initiatives, notably establishing a TransCelerate workstream sharing Placebo and Standard of Care clinical data across 17 companies for use in enhanced clinical trial design. The goal of the workstream is to gain a greater understanding of the placebo effect and apply practical applications of the data to accelerate medicines testing while reducing patient burden. Ed holds an MA in Biology from Brown University, an MBA from Rensselaer Polytechnic Institute, a Master of Science in Electrical Engineering from the University of Rhode Island and a Bachelor of Science in Electrical Engineering from the US Coast Guard Academy. He is currently completing a PhD in Molecular Biology at the University of Miami.
|Daniel Butnaru, PhD||Roche Diagnostics GmbH|
No bio available
|Lawrence Callahan, PhD||FDA|
Chemist, Office of Health Informatics, Global Substance Registration System/Office of Health Informatics, Office of Chief Scientist
Larry is a chemist at the FDA responsible for the development of ISO data standards and the Global Substance Registration System (GSRS). He collaborates with the NIH and other leading researchers in industry and academia on standards and ontologies for regulatory submissions.
|Tanya Cashorali||TCB Analytics LLC|
CEO and Founder
Tanya Cashorali is the founding partner of TCB Analytics, a Boston-based data consultancy. Prior to launching TCB Analytics, she worked as a data scientist at Biogen. Tanya started her career in bioinformatics and has applied her experience to other data-rich verticals such as telecom, finance, and sports. She brings over 10 years of experience using R in data scientist roles as well as managing and training data analysts, and she’s helped grow a handful of Boston startups.
|Vijay Challa||Takeda Pharmaceuticals Inc|
Associate Director, Digital Clinical Platform and Technologies, Data Sciences Institute, R&D
No bio available
|Bing-Yuan Chen, PhD||Genentech Inc|
Lead Informatics Analyst
No bio available
|Xiang Chen, PhD||St Jude Children's Research Hospital|
Assistant Member, Computational Biology
Dr. Xiang Chen is an assistant member in the Dept. of Computational Biology at St. Jude Children’s Research Hospital in Memphis, TN, USA. He is also the member of AACR and ASCB. He received his BS degree in Biochemistry from Fudan University in Shanghai, China, MS degree in Biochemistry in Biochemistry from National University of Singapore in Singapore and PhD degree in Biological Sciences and MS degree in Computational and Statistical Learning from Carnegie Mellon University in Pittsburgh, PA, USA. He has completed his postdoctoral training in Biostatistics at Yale University School of Medicine in New Haven, CT, USA. Dr. Chen’s main research interest is in development and application of novel machine learning based analytical methods for high-throughput, multi-platform omics data in delineating genetic alterations and epigenetic deregulations in pediatric solid tumors, especially those leading to tumor relapse and metastasis. He is also interested in developing experimental models to understand functional roles in tumorigenesis for candidate cancer driver genes emerged after critical evaluation of omics data. Dr. Chen has over 20 years of in-depth research experience in molecular/cellular biology, computer science and statistical genetics and has made major contributions to understanding the genetic and epigenetic landscape of pediatric cancers in both computational method development and data analysis. He has published more than 70 research papers in top-tier, high-impact biomedical journals, including Nature, Nature Methods, Nature Genetics, Cancer Cell, Cell Report, Genome Biology, Nucleic Acids Research and Nature Communications. He has also authored several invited review articles and a book chapter. He is a regular reviewer for scientific journals including Nature, Nature Methods, Nature Communication, Genome Biology, Nucleic Acids Research, Plos Computational Biology, Plos Genetics, Bioinformatics and others.
|Sean Cheng, PhD||Philips Ventures|
Sean is currently an Investment Manager at Philips Ventures, a portfolio of promising health tech companies including Babyscripts, Xealth, Mytonomy, as well as a fund-of-funds to fulfill the Philips Healthtech strategy. He is interested in early-stage investment opportunities in digital health, medical devices and therapeutics.
Previously, Sean held positions at the Boston Consulting Group, the US FDA, and NASA. Sean also serves on the Board of Directors of The Professional Center for Child Development, Board of Advisors at the Johns Hopkins University, and the Advisory Council of the World Economic Forum's Global Shapers Community. Sean holds a PhD in Engineering from the University of Cambridge in England, where he developed expertise in medical device design and optimization algorithms.
Vice President, R&D Operations and Oncology IT
Strategic, visionary leader with an established track record of building and leading multidisciplinary, global Informatics and IS/IT teams, driving change and simplification and delivering value through innovation. Over 20 years experience in the biotechnology and pharmaceutical industry working in both Discovery and Development leading projects, managing complex portfolios, driving change programs, identifying opportunities for strategic initiatives, and translating scientific and medical questions into innovative solutions. Areas of particular strength include: strategy development and implementation, translational medicine, biomedical and health informatics, evidence-based decision makings, scientific and competitive intelligence, and "Big Data" exploitation.
|Michael Conway||National Institute of Environmental Health Sciences (NIEHS)|
Data Systems Architect/Engineer
No bio available
|Seth Cooper, PhD||Northeastern University|
Assistant Professor, Khoury College of Computer Sciences
Seth Cooper is an Assistant Professor in the College of Computer and Information Science and a member of the Playable Innovative Technologies Lab. Prior to joining Northeastern, Seth was the Creative Director of the Center for Game Science at the University of Washington. He previously worked in industry at Square Enix, Electronic Arts, and Pixar Animation Studios. A pioneer of the field of scientific discovery games, Seth’s PhD dissertation, “A Framework for Scientific Discovery through Video Games”, won the 2011 ACM Doctoral Dissertation Award. His work has shown that video game players are able to outperform purely computational methods for certain types of structural biochemistry problems, effectively codify their strategies, and integrate with the lab to help design real synthetic proteins. In addition to developing video games to solve problems and involve the public in science, he’s published research in character animation and crowd simulation.
ITS Digital Innovation Market Lead
Eduardo is the lead for Sanofi’s Digital Innovation. He’s got experience in two successful startups and organizations like Philips Medical and Intel healthcare. Eduardo is a graduate from MIT Sloan.
|Timothy Cutts, PhD||Wellcome Trust Sanger Institute|
Head, Scientific Computing
Tim is responsible for the provision of all the IT services which specifically deliver scientific data and computation. This includes: private and hybrid cloud services; high performance computing (HPC) clusters; high performance filesystems for data analysis; training in the use of HPC and cloud resources; data management systems for scientific data; research and development of IT technologies for solving tomorrow's scientific problems; and, IT support for core business IT systems, included databases, financial and HR systems.The changing focus of the Institute has led to us concentrating on a few areas:
• Scientific reproducibility. Creating IT and informatics systems which enable the portability of scientific analysis between collaborating institutions, and between on premise and other cloud environments, according to scientific need.
• IT Research and Development. Looking further down the road to identify technologies and approaches which could transform today's impossible scientific questions into something tractable and affordable.
• Pre-configured systems. To free the team's time to assist scientists with their computational challenges we are moving, where possible, to pre-configured hardware systems rather than building them by hand. An example area where we are following this approach is in Lustre parallel filesystems. This becomes as easier as these technologies gradually become more mature and mainstream.
• Flexible secure architecture. Science changes all the time, and the approaches to it change all the time. IT technology generally lasts 5 years, which means we must deploy solutions which have the maximum flexibility to adapt to unknown requirements years from now. We are actively promoting and using private cloud infrastructure with software-defined storage and networking to enable scientists to deploy experimental working environments rapidly and without adversely impacting their colleagues.
• Collaboration. We are actively involved in the Global Alliance for Genomics and Health, Health Data Research UK, the Pan-cancer project, and other projects building infrastructures for the sharing and collaborative analysis of large volumes of data.
During his previous role creating and leading the Infrastructure Management Team, he focused on a number of areas:
• Server virtualisation and consolidation. The previous strategy of buying traditional highly available server pairs for providing services was replaced with a virtualisation strategy, going from zero to more than 1000 virtual machines in the course of a couple of years. Virtualisation has now expanded from this established base towards use in computational and data sharing areas.
• Automation. Configuration management of our Linux and Windows estates to minimise the effort in administering thousands of machines.
In the Informatics Support Group, he was an enthusiastic early adopter of blade server technology, deploying our first blade cluster in 2002, squeezing a then-un-precedented 768 cores into just two 19" racks.
He also took part in our early work with parallel filesystems, deploying IBM GPFS for the storing of large shared datasets.
Incyte Genomics (formerly Hexagen)
Here I gained experience on being the customer of scientific IT services, and the skills and techniques needed to run large scale analysis efficiently on limited IT resources.
I developed and ran the company's SNP-calling pipeline, and visualised that data for the senior company scientists.
I was also involved in customer engagement, discussing data needs of customers, and made contributions to the perl framework used by the LifeSeq product to generate and deliver the data to customers.
PhD: Checkpoint Controls in the Latter Half of the Mammalian Cell Cycle
CRC DNA Repair Research Group
Dept of Zoology, University of Cambridge
My research was focused on the contrasting behaviour of human and rodent transformed cell lines with respect to their G2/M phase checkpoints following perturbation of their nucleotide pool levels during S-phase.
|Chris Dagdigian||BioTeam Inc|
Co-Founder and Senior Director, Infrastructure
Bioinformaticist-gone-bad Chris Dagdigian has spent much of the last 15 years designing, building, fixing and improving research-focused HPC and IT systems for use in demanding production computing environments. He occasionally is known to blog, tweet and speak about industry trends and best practices. Formerly of Blackstone Computing and Genetics Institute, Dagdigian specializes in research computing and infrastructure technology issues in the life sciences. A supporter of free software and open standards for life science research, he is a founding member of the Bioperl Project, co-founder of the Bioclusters mailing list and serves on the board of directors as Treasurer of the Open Bioinformatics Foundation.
Senior Vice President, Informatics and Data
Mark has a background in molecular genetics and bioinformatics and has over 15 years of experience working on biomedical data representation, data analysis and application development. In 2001, he joined the London based biotechnology company Inpharmatica, where he was initially working on mining the output of the Human Genome Projects and eventually moved on to building Chemogenomics systems used by pharmaceutical companies, such as Bayer. Mark moved to the European Bioinformatics Institute (EMBL-EBI) as one of the founding members and technical lead for the ChEMBL resource - the largest open-source SAR database. Mark was also responsible for the successful transition of the SureChEMBL chemical patent system from Digital Science to the EMBL-EBI.
|Kevin Davies, PhD|| |
Executive Editor, The CRISPR Journal; Founding Editor, Bio-IT World
Kevin has almost three decades’ experience in science publishing as an editor, journalist, author and publisher. He is the founding editor of Nature Genetics and Bio-IT World magazine and also served as Editor-in-Chief of Cell Press and publisher of Chemical & Engineering News. Kevin is the author of four popular science books including Cracking the Genome, The $1,000 Genome, and an updated version of DNA: The Story of the Genetic Revolution with James D. Watson and Andrew Berry. In 2017, Kevin won a Guggenheim Foundation fellowship in science writing. That same year, he joined Mary Ann Liebert Inc. to spearhead the launch of The CRISPR Journal and join the GEN editorial team. Kevin holds a degree in Biochemistry from Oxford University and a PhD in Human Genetics from St Mary’s Hospital Medical School, London. He carried out postdocs at MIT and Harvard Medical School before joining the editorial staff at Nature. He still clings to a British accent.
|Brandi Davis-Dusenbery, PhD||Seven Bridges Genomics Inc|
As CSO at Seven Bridges, Brandi oversees all aspects of scientific innovation with a focus on creating solutions that accelerate biomedical discovery. Brandi leads the development of collaborative data analysis ecosystems for the National Cancer Institute and National Heart Lung and Blood Institute where she works with stakeholders to shape novel mechanisms and global standards for data access, analytical reproducibility, and usability. Brandi holds a PhD in Biochemistry from Tufts Sackler School of Medicine.
|Guillermo del Angel, PhD||Alexion Pharmaceuticals|
Senior Director, Data Sciences, Genomics and Bioinformatics
Guillermo del Angel, PhD is currently Sr. Director for Data Science, Genomics and Bioinformatics at Alexion Pharmaceuticals in Boston, MA. Since joining Alexion in 2015 he has been leading research efforts focused on applying and developing different machine learning and data science approaches to improve rare disease target discovery, drug development, patient diagnostics and disease characterization. He previously held positions as a consultant at McKinsey & Co. in Mexico City and Boston, and as a computational biologist at the Broad Institute of Harvard and MIT in Cambridge, MA. A native of Mexico City, he originally trained as an electrical engineer and applied mathematician, earning a BS degree from ITESM in Mexico, a MS from Boston University and a PhD from Cornell University.
|Helena Deus, PhD||Elsevier Inc|
Technology Research Director
Dr. Helena Deus is a Technology Research Director for Elsevier Labs. She received her PhD in Bioinformatics from Universidade Nova de Lisboa, where she focused on linked data and semantic web applications for healthcare and life sciences with an emphasis on cancer research. Helena is a data scientist passionate about applying data integration and machine learning techniques to the generation of insights affecting clinical practice and biomedical discovery. Before she joined Elsevier in 2017, Helena's roles included directing a knowledge engineering and data science team at Foundation Medicine and leading projects and strategy for Health Care and Life Sciences at the Digital Enterprise Research Institute, National University of Ireland at Galway (DERI/NUIG). Helena has published over 30 peer reviewed papers. She was one of the winners of the Big Data Track in the 2013 Semantic Web Challenge and of the Linked Data Cup with her work on linking data from The Cancer Genome Atlas.
|John Dey||Fred Hutchinson Cancer Research Center|
Senior HPC Systems Engineer
No bio available
|Jiarui Ding||Broad Institute|
Jiarui Ding is a postdoctoral associate in the Aviv Regev lab at the Broad Institute of MIT and Harvard. Dr. Ding received a PhD in computer science from the University of British Columbia in 2016. His research focuses on developing statistical models and efficient algorithms to learn biologically interpretable latent structures in large-scale, high-dimensional single-cell genomics data, such as those from single-cell transcriptomics, single-cell epigenomics, and spatially resolved methods. He is interested in integrating these datasets generated by cutting-edge single-cell genomics technologies to provide a comprehensive view of biological systems, and understand how they change dynamically under disease perturbations (e.g., food allergy, cancer) and treatments.
|Ariel Dowling, PhD||Takeda Pharmaceuticals|
Director, Digital Strategy Lead, Data Sciences Institute
Ariel V. Dowling, PhD is a Director of Digital Strategy within the Data Sciences Institute at Takeda Pharmaceuticals. In this role, Ariel oversees the strategy, assessment, and deployment of digital devices in clinical studies and related activities across the organization. She advises clinical teams on the selection of digital devices, conducts due diligence on vendors, develops digital sensor implementation protocols and risk mitigation strategies, and assists with data analysis plans for device data. Prior to joining Takeda, she was a Senior Clinical Data Scientist at Biogen Inc where she oversaw the analysis of data from wearable sensors deployed in drug development clinical trials for Parkinson’s Disease. Prior to Biogen, Ariel was the algorithm team lead at MC10 Inc, where she oversaw the development and implementation of algorithms across the full product line and managed all aspects of algorithm testing that lead to a successful FDA submission. She has also worked as a senior research scientist at BioSensics LLC, where she designed algorithms to analyze digital device data from Huntington’s disease patients, stroke patients, and wheelchair users. Ariel holds an MS and PhD in Mechanical Engineering from Stanford University and a BE in Mechanical Engineering from Dartmouth College.
|Dora Elguezabalfsyvdcqwdycvduztwwxqtcbqceraazbrffax||Thermo Fisher Scientific Inc|
|Jake Emerson||The Jackson Laboratory|
Computational Lead, Cube Initiative and Principal Scientific Software Engineer
My professional career started in the US Army Corps of Engineers. While stationed in Alaska, the Marshall Islands, the Republic of Korea and Iraq, I worked as a construction engineer, project manager, explosives and demolitions trainer, and logistics officer. After military service, I have been involved in both the worlds of startups and academia. I have led projects in a variety of fields including: hydrologic warning, field maintenance operations, crisis informatics, oceanographic event analysis, and software development. I have also been an assistant instructor in the Department of Spatial Information Science and Engineering at the University of Maine. I hold a BS in mechanical engineering from the U.S. Military Academy at West Point, and a MS in environmental engineering from the the Missouri University of Science and Technology.
|Phil Eschallier||RCH Solutions|
With more than 25 years experience as a managerial and technical computing professional, Phil currently leads RCH’s Managed Services capabilities and is responsible for all elements of the customer experience, including requirements and resources management, and services definitions and delivery. His professional background includes solutions architecting, scientific and high performance computing design and support, life sciences applications management, and software engineering from both management and technical perspectives.
|Kjiersten Fagnan, PhD||Lawrence Berkeley Natl Lab|
Chief Informatics Officer, Data Science and Informatics Leader, DOE Joint Genome Institute
In April 2016, Dr. Kjiersten Fagnan became the JGI’s Chief Informatics Officer. She responsible for developing and executing the strategic plan for computing and data analysis. Dr. Fagnan joined the JGI in 2012 after completing a petascale postdoctoral fellowship at the DOE National Energy Research Scientific Computing Center (NERSC) and the Computational Research Division at Berkeley Lab. In 2014 Fagnan became the JGI-NERSC Engagement Lead and focused on adapting JGI data-intensive workloads to run on supercomputing hardware. She is also the group lead for NERSC’s Data Science Engagement group and leads efforts to build collaborations between NERSC and other DOE facilities.
|Ian Fore, PhD||NIH NCI|
Senior Biomedical Informatics Program Manager, Center for Biomedical Informatics and Information Technology
Dr. Ian Fore is a Senior Biomedical Informatics Program Manager at the National Cancer Institute’s Center for Biomedical Informatics and Information Technology with a focus on data integration in both basic and clinical science. Current contributions are in managing NIH and NCI interests in data discovery and in establishing Commons for research data. Dr. Fore is an active participant in the Research Data Alliance and FORCE11. He previously led CBIIT’s programs in biorepository and pathology informatics. Previously Dr. Fore worked on drug discovery informatics at Wyeth Research in both the UK and USA, and at Johnson & Johnson Pharmaceutical R&D including developing global databases for research data. He was a product manager at Celera Genomics responsible for programmers interfaces. Prior to leaving the lab for an informatics career Ian gained his DPhil in Physiology at the University of Oxford and subsequently worked as a Research Pharmacologist.
|Xiaowu Gai, PhD||Children’s Hospital of Los Angeles|
Director, Bioinformatics; Associate Professor, Clinical Pathology, Pathology & Laboratory Medicine
I am a human geneticist and a bioinformatician. My primary research interest is in understanding human genetic variations and how they are related to human diseases, including constitutional disorders like mitochondrial diseases and pediatric cancers. I have served as the head of bioinformatics at four different biomedical institutions. Currently, I am an Associate Professor of Clinical Pathology at the Keck School of Medicine of USC, and also the Director of Bioinformatics for the Center for Personalized Medicine at the Children's Hospital Los Angeles. At the Center, we develop and implement a variety of genomics-based tests for both pediatric cancers and for constitutional disorders, including the clinical exome-sequencing test and in particular the OncoKids test for pediatric cancers that we developed in collaboration with Thermo Fisher Scientific. I am responsible for the informatics solutions for all of our tests, which is highly relevant to the proposed research. At the Center, we have been using ClinVar/ClinGen resources and following strictly AMP/ACMG guidelines. I currently serve as a Multi-PI for a NICHD-funded U24 grant, aiming to curate disease-gene and gene-variant pathogenicity assertions in relation to Leigh and Leigh-like syndromes. I have had extensive involvement in many large research projects, having served as PI, Co-PI, or Co-Investigator on a number of university-, hospital-, or NIH-funded grants.
|Jyotin Gambhir, MB, CISM||SecureFLO LLC|
Jyotin Gambhir (Founder/Consultant | SecureFLO, LLC| SECaaS – Security as a Service) GRC | SECaaS | DaaS | IDM | WAF | Security Architecture | DDOS | Compliance| Policy Development| | SaaS Introduction Mr. Gambhir has an extensive experience in Information Security, Risk, Privacy, and technology. He has worked with a wide array of clients in varying verticals for over eighteen (18) years. My most recent experience in the CISO role is building an IT Risk Management Program, focused on IT security for a large Healthcare organization network in the Northeast. Jyotin has experience in Financial Services, Retail, Research and Development, Biotechnology/Pharmaceutical, Healthcare, and the Government sectors. At Deloitte, he worked for six years in managing large projects at Fortune 100 companies. His teams deployed complex solutions for some of the largest financial services, state and federal government, and telecom industry clients. Jyotin has worked extensively with senior management and board of directors to develop strategies, vision, and direction for Information security programs. He has hands on experience started in security operations on mainframe environments, which encompassed the areas of privacy and security regulations, data protection, vulnerability management, operational security, and identity and access management. His current focus has on the data lifecycle within businesses and looking at each aspect of security from data creation to its destruction and disposal. Jyotin’ has developed frameworks to manage various aspects of the information security programs using NIST, ISO, HI-TRUST, CIS and other standards and models. This standards-based approach provides the ability to address multiple areas of compliance and regulations and provides for consistency. Prior to joining SecureFLO, LLC, Mr. Gambhir was with recognized consulting firms such as Deloitte, Tivoli/IBM, and BMC Software. During his current and past tenures, he has delivered successful initiatives across multiple industries such as Telecommunications, Energy, Healthcare/ Pharmaceuticals, Federal Government, Financial Services, Higher Education, Manufacturing, and Law Enforcement.
|Victoria Gamerman, PhD||Boehringer Ingelheim|
Head of US Health Informatics and Analytics
As the Head of Health Informatics and Analytics (HIA), Victoria leads a team of experts in cross-functional collaborations on various initiatives within the competitive environment to optimize BI’s ability to meet current and emerging needs for Real World Evidence to help meet patients’ needs. The HIA team at Boehringer Ingelheim is a global team uniquely positioned to leverage the rich information from Real World Data using advanced analytics for Big Data through close collaborations with internal/external partners to foster efficient patient-oriented clinical development programs. Prior to leading the HIA team, Victoria worked as both a project and trial statistician providing expert advice in designing and analyzing data from various sources using appropriate analytic and statistical techniques. She earned her PhD in Biostatistics and Master’s in Biostatistics from the University of Pennsylvania’s Perelman School of Medicine and a Master’s and Bachelor’s in Mathematics from Boston University. She currently also teaches at Columbia University.
Director, Data Analytics, Data Science Institute
Yan Ge is the Director of Data Analytics in the Data Sciences Institute at Takeda Pharmaceuticals. An industry veteran with over 20 years of experience in the Life Sciences and Healthcare, Yan has built up Analytics and Data Science capabilities at three different companies including Takeda. His focus in Takeda are research including discovery, translational and real-world plus applications of AI/ML to address R&D challenges. Before Takeda, Yan served in data analytics leadership roles in Ascensia Diabetes, Telcare, Deloitte Consulting, Medidata and IBM among others. Yan holds multiple graduate degrees in Statistics, Molecular Biosciences and MBA with his BSc in Applied Chemistry from Peking University, China.
|Nils Gehlenborg, PhD||Harvard Medical School|
Assistant Professor, Department of Biomedical Informatics
Nils Gehlenborg received his PhD from the University of Cambridge and was a predoctoral fellow at the European Bioinformatics Institute (EMBL-EBI). The goal of Gehlenborg’s research is to improve human health by developing computational techniques and interfaces that enable scientists and clinicians to efficiently interact with biomedical data. Tight integration of algorithmic approaches from biomedical informatics with advanced data visualization techniques is central to his efforts, as is close collaboration with clinicians and experimentalists. Currently, Gehlenborg is researching and developing novel tools to visualize heterogeneous data from large-scale cancer genomics studies such as The Cancer Genome Atlas, integrating visual and computational approaches to support sense-making in biology, and using software to support reproducible collaborative research in epigenomics and genomics. Gehlenborg is a co-founder and former general chair of BioVis, the Symposium on Biological Data Visualization, and co-founder of VIZBI, the annual workshop on Visualizing Biological Data. Occasionally, he contributes to the “Points of View” data visualization column in Nature Methods. Gehlenborg currently serves as the Director of the Master of Biomedical Informatics (MBI) program at Harvard Medical School.
|Laura Goetz, FACS, MD, MPH||City of Hope Comprehensive Cancer Center|
Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Division of Clinical Cancer Genomics
The daughter of a doctor and a public health nurse, Laura H. Goetz, MD, MPH, knew early on she wanted to become a physician and help others. Along the way she became a decorated U.S. Army veteran, a talented cancer surgeon and a fierce believer in using every available tool – from public education campaigns to the latest genetic breakthroughs – to help prevent cancer.
Dr. Goetz holds a medical degree from University of Minnesota and a Masters in Public Health from University of California Berkeley. She is certified in cancer genetic risk assessment and most recently directed the Cancer Prevention and Early Detection program at TGen (Translational Genomics Institute), City of Hope’s genetic research affiliate. She is passionate about the new field of “precision prevention” which collects detailed data on cancer mechanisms, inherited risks and environmental factors to create a specialized prevention plan for each patient.
Dr. Goetz is a lieutenant colonel in the U.S. Army Reserve Medical Corps. She served in Operation Iraqi Freedom and earned the Army Commendation Medal and Combat Action Badge, both in 2011.
|David Gosalvez, PhD||PerkinElmer|
No bio available
|Robert Green, MD, MPH||Brigham & Women’s Hospital, Broad Institute, and Harvard Medical School|
Professor of Medicine (Genetics) and Director, G2P Research Program/Preventive Genomics Clinic
Robert C. Green, MD, MPH is Professor of Medicine (Genetics) at Harvard Medical School and a physician-scientist who directs the G2P Research Program at Brigham and Women’s Hospital and the Broad Institute. Dr. Green is internationally recognized for research and policy efforts accelerating the implementation of genomic/precision medicine.
Education and Training: Dr. Green graduated Amherst College and University of Virginia School of Medicine, with MPH in epidemiology from Emory University School of Public Health. His specialty training was at Harvard Medical School residencies and he is board certified in both neurology and medical genetics.
Research Achievements: Dr. Green led the first experimental trials disclosing common complex disease risk (REVEAL Study) and the first prospective studies of direct-to-consumer genetic testing services (PGen Study). He currently leads and co-leads the first NIH funded randomized trials of sequencing in adults (MedSeq Project), newborns (BabySeq Project), and active duty US military personnel (MilSeq Project). He created the concept of aggregate penetrance of genomic variants in prospective population cohorts and is demonstrating the feasibility of genomic sequencing in healthy newborns, paving the way for humans to gain lifelong medical benefits from genomics. With continuous funding from NIH for 26 years he has published more than 300 papers with an h index of 90. In 2014, he won the Coriell Prize for Scientific Achievement in Personalized Medicine, and in 2019 was named by BIS Research as one of the 25 most influential voices in precision medicine. Since joining the Harvard Medical School faculty in 2011, the G2P research team has been awarded research support of over $49 million.
Research Leadership: Dr. Green recently co-chaired the Steering Committee of both the Clinical Sequencing Exploratory Research program (18 NIH grants, over 300 investigators), and the Steering Committee of the Newborn Sequencing in Genomic Medicine and Public Health program (4 NIH grants, over 100 investigators) and is a co-investigator on the Boston site within the Electronic Medical Records and Genomics Network. He is Associate Director for Research of Partners HealthCare Personalized Medicine and is leading the development of protocols for return of genomic results for the All of Us Research Program of the United States Precision Medicine Initiative and the Google/Verily Project Baseline.
Policy Leadership: Dr. Green is accelerating the worldwide implementation of medical genomics. He was lead author on the influential recommendations for managing incidental findings in clinical sequencing from the American College of Medical Genetics and Genomics and contributing author on recommendations for managing incidental findings in research biobanks among participants and among family members of participants. He is a Board Member of the Council for Responsible Genetics and works within the Global Alliance for Genomics and Health and the All of Us Research Program on designing efforts to return research information, particularly genomic information, to research participants.
Clinical Care: Dr. Green directs the Preventive Genomics Clinic at Brigham Health, providing evidence-based genomic and multi-omics evaluation to early adopters seeking to anticipate and prevent future illness.
Entrepreneurship: Dr. Green co-founded Genome Medical, a telegenomics technology and services company providing genetics expertise to patients, providers, employers and healthcare systems.
Presentations & Media: Scientific plenary presentations include American College of Medical Genetics/Genomics, Cold Spring Harbor, AGBT, European Society for Human Genetics and BioData World. Presentations to business include Forbes Healthcare Summit, World Science Festival, Future of Genomic Medicine, Exponential Medicine, Festival of Genomics, Aspen Ideas Festival, SXSW, Asian Healthcare Leadership and JP Morgan. His work and commentary have been featured on PBS television/radio, NBC Nightly News, CBS Sunday Morning, Today Show, CNBC, the Doctors, New York Times, Wall Street Journal, Time Magazine, New Scientist, FastCompany, GenomeWeb, Gizmodo and Buzzfeed. Research findings from Genomes2People Research are highlighted in these podcasts, blog posts and videos.
Research Support: Dr. Green’s research is supported by grant funding from the National Institutes of Health, the Department of Defense, the Snite Foundation and the Franca Sozzani Fund for Preventive Genomics.
Disclosures: Dr. Green receives compensation for advising the following companies: AIA, Applied Therapeutics, Humanity, Verily; and is co-founder of Genome Medical, Inc, a technology and services company providing genetics expertise to patients, providers, employers and care systems.
|Nigel Greene, PhD||AstraZeneca Pharmaceuticals|
Director, Head, Data Science and Artificial Intelligence, Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences
Nigel Greene leads the Data Science and Artificial Intelligence department in Clinical Pharmacology and Safety Sciences at AstraZeneca and is interested in the application of artificial intelligence methods to understand of mechanisms of drug-induced toxicity and their translation to a clinical patient population. Previously Dr. Greene was a head of the Predictive Compound ADME and Safety group at AstraZeneca. Dr Greene also spent 14 years at Pfizer, Inc. where he started in Drug Safety R&D and later transitioned to the Compound Safety Prediction group in Medicinal Chemistry. In his early career, Dr. Greene worked for Lhasa Ltd. where he pioneered computational toxicology, and for Tripos, Inc.
Nigel’s other activities outside of AstraZeneca have included being the Chair of the Board of Trustees for Lhasa Ltd. and he has served on multiple National Research Council committees sponsored by the US Environmental Protection Agency, US Food and Drug Administration, and the National Institutes of Health.
Dr. Greene received his BSc and PhD from the University of Leeds in the UK.
|Susan Gregurick, PhD||National Institutes of Health|
Associate Director, Data Science (ADDS) and Director, Office of Data Science Strategy (ODSS)
Susan K. Gregurick, PhD, was appointed Associate Director for Data Science and Director of the Office of Data Science Strategy (ODSS) at the National Institutes of Health (NIH) on September 16, 2019. Under Dr. Gregurick’s leadership, the ODSS leads the implementation of the NIH Strategic Plan for Data Science through scientific, technical, and operational collaboration with the institutes, centers, and offices that comprise NIH. Dr. Gregurick was instrumental in the creation of the ODSS in 2018 and served as a senior advisor to the office until being named to her current position. Dr. Gregurick was previously the Division Director for Biophysics, Biomedical Technology, and Computational Biosciences at the National Institute of General Medical Sciences (NIGMS). Her mission in this role was to advance research in computational biology, biophysics and data sciences, mathematical and biostatistical methods, and biomedical technologies in support of the NIGMS mission to increase our understanding of life processes. In this role Dr. Gregurick led the institutes effort to reimagine the NIGMS technology programs including early stage, concept development, focused technology programs, development and dissemination centers, through National and Regional Resources to support state-of-the-art facilities, equipment, technologies, research tools, software, and service. Prior to joining the NIH in 2013, Dr. Gregurick was a program director in the Office of Biological and Environmental Research at the Department of Energy (DOE). In this role, she developed the information and data sharing policy for the agency’s Genomics Science Program and oversaw the development and implementation of the DOE Systems Biology Knowledgebase, a framework to integrate data, models, and simulations together for a better understanding of energy and environmental processes. Dr. Gregurick is an advisory council member for the DOE’s Office of Advanced Scientific Computing Research and a member of two National Science Foundation advisory committees – the Biological Sciences Advisory Committee and the Computer and Information Science and Engineering Committee. She has received several awards during her tenure at NIH, including two NIH Director’s Awards. Before beginning a career of government service, Dr. Gregurick was a professor of computational chemistry at the University of Maryland, Baltimore County. Her research interests included dynamics of large biological macromolecules, and her areas of expertise are computational biology, high performance computing, neutron scattering and bioinformatics. Dr. Gregurick received her undergraduate degree in chemistry and mathematics from the University of Michigan and her PhD in physical chemistry from the University of Maryland. She completed a Lady Davis postdoctoral fellowship at Hebrew University in Israel and a Sloan postdoctoral fellowship at the University of Maryland’s Center for Advanced Research in Biotechnology, now the Institute for Bioscience & Biotechnology Research, in Shady Grove, Md.
|Robert Grossman, PhD||University of Chicago|
Frederick H. Rawson Distinguished Service Professor in Medicine and Computer Science; The Jim and Karen Frank Director, Center for Translational Data Science
Robert L. Grossman, PhD, is the Frederick H. Rawson Distinguished Service Professor in Medicine and Computer Science and the Jim and Karen Frank Director of the Center for Translational Data Science at the University of Chicago. He joined the faculty in 2010 and has served as the chief research informatics officer of the Biological Sciences Division since 2011. He is the principal investigator for the National Cancer Institute Genomic Data Commons (GDC), a platform for the cancer research community that manages, analyzes, integrates, and shares large-scale genomic datasets in support of precision medicine. The GDC was used by more than 100,000 researchers in the past year. He has also built data commons to support research in other areas, including cardiology, infectious diseases, neuroscience, and the environment. His research interests include data science, machine learning, and deep learning. He is a member of the Frederick National Laboratory Advisory Committee for the National Cancer Institute and of the Science Advisory Board for the National Oceanic and Atmospheric Administration. He earned his PhD in applied mathematics at Princeton University and an AB in mathematics from Harvard University.
|Rishi Gupta||AbbVie Inc|
Principal Research Scientist, Data Science and Informatics
Rishi R. Gupta is currently a Principal Research Scientist at Abbvie, Inc. at Lake County, Chicago. He leads the Cheminformatics and Competitive Intelligence groups. At AbbVie, he has developed a web based infrastructure to expose suite of Cheminformatics tools called AIDEAS. He has developed and deployed machine learning models for a variety of bioassay data including ADMET endpoints. In his extended role within Competitive Intelligence (CI), Rishi is developing web based visual-analytic frameworks for exposing genomics data, clinical Trials data and a variety of other CI related landscapes e.g. KOLs. Prior to AbbVie, Rishi was at Pfizer Global Research and Development as a Computational Chemist where he had broad set of responsibilities ranging from developing ADMET in-silico models, novel scoring methods such as confidence metrics for in-silico models. He also supported the Anti-Bacterial research organization. Rishi earned his PhD from University of Connecticut where he developed systems engineering approaches for genetic pathway analysis and also developed computational methods for application in drug discovery.
|Shweta Gupta||Cambridge Consultants Inc|
Director, Global Medical Technology
No bio available
|Karl Gutwin, PhD||BioTeam Inc|
Senior Scientific Consultant
Karl joined BioTeam in 2017 with a background in cloud, high-performance computing and scientific computing applications. He focuses on complex system architecture, implementation and support, particularly for informatics workflows in data science and the life sciences. Karl received his PhD from the Massachusetts Institute of Technology, studying methods for predicting protein-protein interaction structure. He then joined Biogen, where he worked as a scientific application support specialist and HPC administrator, before joining Biogen’s Data Sciences group as a data engineer. There, Karl was part of a team that brought in high-speed cloud and collaboration connectivity with Internet2 and AWS, and built a dynamically reconfigurable computing environment for data science exploration. Having moved to Biogen’s Scientific Computing group, Karl worked to build a cloud HPC capable of performing multi-sample joint exome calling on tens of thousands of samples in a week. He also led a team of developers building end-to-end workflow automation for NGS pipelines.
|Farhan Hameed, MD||Pfizer Digital|
VP, Global Real World Data – Strategy, Analytics & Insights (GRWD-SAI), Analytics, Informatics & Business IntelIigence (AIBI)
Farhan "CJ" Hameed is a biomedical informatician and real-world data strategist with diverse experience in healthcare, spanning academia, patient care, clinical research and informatics for over 18 years. In his current role at Pfizer, he focuses on development and harvesting strategic alliances for end-to-end utilization of real-world data (RWD) in drug development to generate regulatory grade real-world evidence (RWE). In his earlier work at Pfizer, CJ led Informatics initiative at the Quantitative Medicine and Neuroscience Research Units and steered the development and implementation of semantically driven interoperable drug discovery analytics platforms and knowledge management systems for multiple therapeutic areas. In Digital Medicine group and Pfizer Innovative Research (PfIRe) Lab, his team led the development of analytics-based reporting systems leveraging AI & Machine Learning by incorporating ontologies, clinical and wearables data standards for the real world and clinical trial studies. Prior to joining Pfizer, CJ led several clinical informatics projects, built multi-specialty evidence-based knowledgebase systems in partnership with several international academic institutes and publicly funded organizations and steered development of international drug databases, and clinical decision support systems (CDSS). He also held several academic positions in the past – an Associate Professor at the College of Pharmacy at Chicago State University and Midwestern University and, currently, teaches at Northeastern University, Boston Health Informatics graduate program. CJ holds a master's degree in health informatics from Northeastern University and a medical degree from Dow University of Health Sciences. He is a HIMSS fellow and recently attained American Medical Informatics Association fellowship status.
|Ian Harrow, PhD||Pistoia Alliance Inc|
Consultant Project Manager and Manager, FAIR Implementation and Ontologies Mapping Project
Ian Harrow manages the FAIR Implementation and Ontologies Mapping Projects for the Pistoia Alliance. He is an indepenedent consultant providing expert project management and data analytics for real world problems. His consultancy is also a partner for the BioExcel Centre of Excellence for Biomolecular Research. He has over 30 years experience working in and for the Pharmaceutical and Life Science industry and obtained a PhD from the University of Cambridge, UK.
|Samiul Hasan, PhD||GlaxoSmithKline|
Scientific Analytics and Visualization Director, Data and Computational Sciences
Samiul Hasan is a director within the Scientific Analytics Visualization team at GSK. Samiul’s passion is in using computational techniques including semantic technologies to enhance scientific decision making and increase the chances of getting better treatments to patients more quickly. Prior to his current role, Samiul was with GSK’s Computational Biology group for over 10 years. In that time, he implemented several analysis pipelines for critical GSK drug projects and was instrumental in developing widely used technical infrastructure including OpenTargets. Before his GSK career, Samiul completed a 2-year Bioinformatics postdoctoral fellowship at the Novartis Institute of Tropical Diseases in Singapore where he applied machine learning approaches for prioritizing drug targets in pathogens. This came after his PhD in Bioinformatics at the Wellcome Trust Sanger Institute/University of Cambridge where he was applying similar methods for predicting regulatory regions in human DNA.
|Neda Hassanpour, PhDfsyvdcqwdycvduztwwxqtcbqceraazbrffax||Takeda Pharmaceuticals Inc|
No bio available
|Qais Hatim, PhD||U.S. Food and Drug Administration|
Successful statistician/operation research analyst and industrial engineering professional with experience in univariate/multivariate statistical techniques, categorical data analysis, analysis of variance/covariance (ANOVA/ANCOVA) and multivariate analysis of variance/covariance (MANOVA/MANCOVA), performing testing procedures utilizing reliability analysis tools, censored data analysis, using stochastics processes in modeling reliability problems, structured and unstructured data mining, design of experiment, process control, simultaneous statistical inference, Bayesian modeling, sustainable and agile manufacturing dynamic system modeling and simulation, large-scale optimization, development of analytical tools and scalable computational schemes for optimization and equilibrium problems, real-time big data analytics for manufacturing system, and supply chain management. Recognized as a self-starter and quick learner with providing exceptional, innovative, and efficient solutions to business problems through a profound knowledge of the underlying physics and mathematics as well as computational tools, written and verbal communication skills, and excellent work ethic.
|Richard Head, MS||Washington University School of Medicine|
Professor, Genetics and Pathology & Immunology; Director, Genomics, McDonnell Genome Institute Genetics; Genome Technology Access Center at the McDonnell Genome Institute (GTAC@MGI)
As the Director of Genomics at the McDonnell Genome Institute (GTAC@MGI), I bring 28 years of experience in medical research, with more than 22 years in the development and application of high-throughput genomic technologies (next generation sequencing, microarray, and high-throughput PCR). In addition to large-scale data generation, I also maintain considerable expertise in the analysis and interpretation of the same, particularly with regards to drug discovery, clinical research and patient care. In my years within the pharmaceutical industry and academia, I led numerous successful efforts in the discovery of novel drug targets, identification of drug mode of action, biomarkers for patient stratification, elucidating the translatability of pre-clinical models, and ascertaining the causes for drug failures. My current primary research interests focus on the development of novel interpretive analytical methods for multi-omics data and their use in the areas of inflammation & immunology, oncology, and cardiovascular & metabolic diseases.
|Allison Heath, PhD||Children’s Hospital of Philadelphia|
Director, Data Technology and Innovation, Center for Data-Driven Discovery in Biomedicine (D3b)
Allison Heath is the Director of Data Technology and Innovation responsible for providing technical and collaborative leadership to build platforms for data-driven discovery that span across both research and operational efforts. She provides supervision of the data products and platforms team which performs basic and applied research in data intensive computing, bioinformatics, cloud computing, and related areas. Since joining CHOP in 2017, Allison and her team have been working on solving big data challenges in the unique context of pediatric diseases, including leading the development of the Kids First Data Resource Center (DRC).
|Michael Heinke||Bayer Business Svcs GmbH|
Director, Global Pharma Strategy
Michael is driving digital transformation and new digital business models in close collaboration with the functional representatives at Bayer Pharma. This includes identification and prioritization of new digital business opportunities as well as the build-up of critical capabilities as well as fostering the needed cultural changes and talent management. Before he joined Bayer he worked in Strategy Consulting focusing on the digitalization of Healthcare and the concomitant convergence of industry. He helped various global leading Pharma clients to leapfrog existing business models and digital solution by creating truly customer centric offerings and enhancing the analytics driven utilization of various internal and external data. Prior to that he worked at the pharmaceutical industry in multiple Commercial and Medical line management positions at global and country level.
Georges founded Databiology in 2013 to provide a biomedical information management and orchestration platform for the life sciences and healthcare sectors. Under his leadership and product vision, Databiology has grown into an established global company with offices in the US, UK, Hong Kong and Mexico with a leading platform solution for globally distributed biomedical data, applications and infrastructure.
|Peter Henstock, PhD||Pfizer Inc|
AI & Machine Learning Technical Lead
Peter Henstock is working to transform Pfizer using AI and Machine Learning. He is the Machine Learning and Technical Lead in Pfizer’s Digital group based in Massachusetts. He holds a PhD in Artificial Intelligence from Purdue University and Master’s degrees in Biology, Software Engineering, Statistics, Applied Linguistics, and Image Processing. Before joining Pfizer, Peter worked at MIT Lincoln Laboratory in image processing and computational linguistics. He also teaches graduate level Machine Learning & Data Mining and Software Engineering at Harvard University.
|Spencer Hey, PhD||Harvard Medical School|
Faculty and Co-director of Research Ethics
Dr. Hey is a faculty member and Co-Director of Research Ethics at the Harvard Center for Bioethics. He received his PhD in philosophy from the University of Western Ontario and BA (Honors) in philosophy from the University of Illinois at Chicago. He previously held a postdoctoral fellowship in the Biomedical Ethics Unit at McGill University and a visiting scholarship at Oxford University.His research interests lie at the intersection of biomedical ethics and philosophy of science—with a focus on clinical trials and ethical challenges across the drug research and development enterprise. His published work has appeared in scientific, medical, bioethics, and philosophical venues, including Science, Neurology, The BMJ, PLoS Medicine, STAT News, Journal of Medical Ethics, Hastings Center Report, Perspectives in Biology and Medicine, and Philosophy of Science.
Sara Nygaard has 9 years of experience in applying biological interaction (PPI) network analyses to enhance performance in pharma projects within target and biomarker discovery, treatment response and drug repositioning. Now, she is dedicated to bringing some of these tools into the hands of pharma R&D scientists, through Intomics’ inBio platform that allows for advanced data analyses and biological interpretation in the context of high confidence PPI-maps and supports collaboration between bioinformaticians and biological scientists.
|Xinjun Hou, PhD||Pfizer|
Director, Computational Chemistry
No bio available
|Michael Huang||Thermo Fisher Scientific|
Product Manager, Digital Science
No bio available
|Yu-Shan Huang||Daopin Incorporation|
No bio available
|Hongmei Huang, PhD||Roche Genentech|
Senior Director, Head of Development Sciences Informatics, Development Sciences
Hongmei Huang is the Head of Informatics for Development Sciences at Genentech, a member of the Roche Group. In this role, she is responsible for the strategic leadership around data management, informatics systems and analytics platforms for translational research and development functions including Biomarker Development and Safety Assessment. She also serves on the leadership team for the Roche wide effort to make data FAIR across R&D. Hongmei is an accomplished Informatics leader with 25 years of experience in the Pharmaceutical/Biotech Industry. She started her career as a Research Investigator and transitioned into Informatics over the course of her career, with leadership roles in various companies including Novartis and Johnson & Johnson.
|Bonnie Hurwitz, PhD||Univ of Arizona|
Assistant Professor, Biosystems Engineering
Dr. Bonnie Hurwitz is an Assistant Professor of Agricultural and Biosystems Engineering at the University of Arizona and Bio5 Research Institute Fellow. She has worked as a computational biologist for nearly two decades on interdisciplinary projects in both industry and academia. Her research on the earth and human microbiome incorporates large-scale –omics datasets, high-throughput computing, and big data analytics to answer questions in systems biology. In particular, Dr. Hurwitz is interested how viruses re-engineer host metabolism and the implications on host-driven processes. Dr. Hurwitz is well-cited for her work in computational biology in diverse areas from plant genomics to viral metagenomics with over 2600 citations.
|Daniel Huston||Bristol-Myers Squibb Co|
Lead IT Business partner, Translational Bioinformatics IT for Translational Medicine
No bio available
|Michael Iarrobino||Copyright Clearance Center|
Director, Product Management
Mike Iarrobino is Director of Product Management for CCC'saward-winning content and rights workflow suite, RightFind®. He has previously managed marketing technology and content discovery products at FreshAddress, Inc., and HCPro, Inc. He speaks at webinars and conferences on the topics of content discovery and data management.
|Yuval Itan, PhD||Icahn School of Medicine at Mount Sinai|
Assistant Professor, Department of Genetics and Genomic Sciences; Members, Charles Bronfman Institue for Personalized Medicine
Dr. Yuval Itan is an Assistant Professor in the Department of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genomic Technology and a core member of The Charles Bronfman Institute for Personalized Medicine, at the Icahn School of Medicine at Mount Sinai in New York City. The main focus of the Itan lab is investigating human disease genomics for enhancing precision medicine, by developing new computational methods to detect disease-causing mutations and genes in next generation sequencing data of patients, and by performing cases-controls studies of patient cohorts to identify new genetic etiologies of human diseases. The Itan lab applies and combines diverse approaches across computer science and biology, including machine learning, natural language processing, bioinformatics, statistical genomics, modelings and simulations, and population genetics. Education: BSc, Bar-Ilan University; PhD, University College London;
Postdoc, The Rockefeller University.
Associate Director, Global Data Science
Adam is the Lead Data Scientist at Biogen, where he works on optimizing commercial outcomes through marketing, patient outreach and field force infrastructure utilizing data science and predictive analytics. Biogen is a leader in the treatment and research of neurological diseases for 40 years. Prior to being commercial lead, Adam was part of their Digital Health team where he worked on next generation application of wearable and neurological tests. Holding a PhD in genomics, he also teaches management skills for data science and big data initiatives at Boston College.
|Ewa Jermakowicz||Roche Pharma|
IT Business Partner for PD Scientific Decision Support
Ewa Jermakowicz is an IT Business Partner in the Scientific Decision Support Network at Roche, supporting Biometrics and wider Product Development activities. Her current focus is on processes and tools supporting FAIRification of data coming from clinical trials. She's an IT Lead implementing a Platform allowing to pool clinical data with molecular, genomics and digital biomarkers for diverse therapeutic areas to fully capitalize Roche scientific data in support of Reverse Translation. Prior to this role she has been the Informatics Project Manager leading number of global multimillion projects in the clinical and real world data space. She has been with the company for 10 years with previous experience in a global financial institution.
|Bino John, PhD||AstraZeneca Pharmaceuticals|
Associate Director, Data Science - Clinical Pharmacology & Safety Sciences
Bino John, PhD, currently leads a variety of Artificial Intelligence (AI) Initiatives at AstraZeneca (AZ). As an Associate Director at AZ, he is leveraging Deep learning and other advanced AI approaches to accelerate Drug development. Before joining AZ in 2018, Bino led a variety of computational biology initiatives and teams at Dow and then Dow-DuPont. In those roles, his efforts included enabling machine learning/AI and integrative big-data informatics capabilities for genomics research for the Agricultural Sector. He earned an Integrated Master’s degree in Chemistry from the Indian Institute of Technology (Mumbai) in 2000 and subsequently received his PhD from The Rockefeller University in Biomedical Sciences in 2003. His thesis research in computational structural biology with Dr. Andrej Sali was followed by postdoctoral studies in computational genomics with Dr. Chris Sander at the Memorial Sloan-Kettering Cancer Centre. In 2005, Bino joined the University of Pittsburgh as a faculty, where he focused on using high-throughput methods for cancer biomarker discovery, resulting in the discovery of novel molecules and molecular pathways.
|Graham Jones, PhD||Novartis Horsham Research Ctr|
Director, Innovation, Technical Research and Development
Following his PhD at Imperial College London, Graham was a NATO fellow at Harvard University where he worked with Nobel Laureate E. J. Corey. His independent academic career spanned 25 years and generated >$100 million external funding and 160 peer reviewed publications in the fields of drug discovery, drug delivery, process technology, regulatory science and medical devices. He held a number of leadership roles in the academy including pro-vice chancellor, vice provost and institute director, most recently Professor of Medicine and Director of Translational Research at the Tufts Clinical and Translational Science Institute (CTSI) in Boston MA. In 2018 Graham was recruited by Novartis as Director of Innovation. Graham has been a regular consultant to the pharmaceutical and biotechnology industry and was an advisor to the FDA in the development of the biosimilars approval pathway. He has also been instrumental in establishing and advising a large number of technology-based startup companies who have subsequently raised >$4B in venture funding. Graham sits on several advisory and editorial boards and has been the recipient of numerous awards for scientific and technology development. He was awarded the DSc in 2006 for contributions to medicinal chemistry.
|Jaidepp Joshi||Stelus Technologies|
Staff Solutions Engineer, Engineering
IT professional with over 20+ years of experience developing IT solutions. Solving unique data storage related challenges for life science organizations, in the areas of genomics, computational biology, and protein structure prediction. Primary focus on High Performance Storage with technologies such as HPC, Next Generation Sequencing, and High Speed Microscopy.
|Sanjay Joshi||Dell EMC|
Industry CTO, Healthcare
Sanjay Joshi is the chief technology officer for healthcare and life sciences in the emerging technologies division of Dell EMC. Based in Seattle, Sanjay's 28-plus year career has spanned the entire gamut of life sciences and healthcare from clinical and biotechnology research to healthcare informatics to medical devices. His current focus is a systems view of genomics, proteomics and healthcare for infrastructures and informatics.
|Natalija Jovanovic, PhD||Sanofi|
Chief Digital Officer
Natalija Jovanovic is the Chief Digital Officer at Sanofi Pasteur, the vaccines division of Sanofi. She has extensive experience in delivering digital solutions at AIG, the global insurer, and as VP of Innovation at Brown Brothers Harriman, a global commercial bank. Previously, Natalija was at McKinsey, the strategy consulting firm, and holds a PhD in electrical engineering from MIT.
Chief Data Officer
Milind Kamkolkar is the CDO of Cellarity. Milind is leading Cellarity’s diverse AI and Digital organization, which implements machine learning science on a digital biology landscape to explore new clinical hypotheses that can alter cell behaviors. Milind joined Cellarity from Sanofi where he was the first enterprise Chief Data Officer in the pharmaceutical industry. Milind’s focus was transforming Sanofi from a data-generation organization into a data-driven organization, to empower the lives of patients and enrich the value Sanofi delivered to customers. The approach was drawn from his tenure at Novartis where he was the Global Head of Data Science and AI in Digital Medicines. Milind is a featured speaker (TEDx), Business Transformation Top 150 Leader and thought leader in digital health, AI and big data. Milind has served as a board advisor and mentor to numerous startups, founders and VC firms focused on entering the life science space through digital, data or AI. He has served as an Honorary Lecturer for Physician Entrepreneurship at BartsX, Faculty at Exponential Medicine and a Former Special Advisor to the UN Global Compact Sustainable Development Goals program.
|Gurpreet Kanwar, MBA, PMP||NAV CANADA|
Senior Manager, Project Delivery Service
Gurpreet has been working as Project manager for more than 14 years with experience of 21 years in IT technical project planning and implementation industry. He helped establishing the PMO at his company and has managed many complex projects globally. Gurpreet works closely with customers and portfolio managers to help them resolve specific issues and problems regarding the projects. Gurpreet has MBA Degree from Edinburgh Business School.
Senior Software Engineer National Center for Advancing Translational Science
Danny Katzel has been a Senior Software Engineer at NIH’s National Center for Advancing Translational Sciences (NCATS) through RanchoBiosciences for the past 4 years. While at NCATS, Mr. Katzel has worked on the Global Substance Registration System, G-SRS, which provides a common identifier for all of the substances used in medicinal products, utilizing a consistent definition of substances globally, including active substances under clinical investigation. Previously, Mr. Katzel worked at The Institute for Genomic Research (TIGR) which later became the J. Craig Venter Institute (JCVI). During the 10 years he worked there, Danny was the lead Software Engineer for the Viral Genomics Group where he wrote the key components of most of the pipelines that have been used to sequence, assemble, analyze, annotate, and publish over 20,000 viral genomes to Genbank.
Principal Scientist, Translational Sciences
Erik Koenig has been a strategic leader in genomic sciences and computational biology focused on translational biomarker development including PD, resistance, safety and predictive patient selection ranging from protein homeostatis, targeted, ADC and immuno-oncology programs. Currently at Takeda, Erik is provide leadership for cross-functional strategic initiatives, like STORK, and plays a key role in fostering collaborations with functional and scientific leaders to innovate and operationalize transformative translational strategies aligned for patient benefit.
|Ivan Krstic, PhD||Elsevier Inc|
Director, Chemistry Solutions
No bio available
|Hande Kucuk McGinty, PhD||Collaborative Drug Discovery|
Hande is a research scientist at CDD. She has been working with the BioAssay Express development team. Her most recent research focuses on bio-ontologies and their applications for artificial intelligence and machine learning.
Global Director - Emerging Technologies
No bio available
|Amir Lahav, ScD||Karyopharm Therapeutics, Inc.|
Digital Medicine and Innovation Lead; Digital Healthcare Intelligence, Mitsubishi Tanabe Pharma
Amir is a clinical neuroscientist specialized in digital medicine and digital health strategy. As a former Digital Health and Clinical Innovation Lead at Pfizer, Amir has developed a strategic vision focused on patient-centered outcomes empowered by real-world data to enable the discovery of clinical insights otherwise not possible solely based on conventional health records. Drawing on his experience in the healthcare sectors, healthtech startups, and the drug development cycle, Amir brings an entrepreneurial zeal to the clinical world through innovation thinking and digital solutions from proof of concepts to scale-up solutions. Amir has boundless passion for accelerating novel therapies and creating a path for better patient experience. Prior to pharma, Amir was a professor of Pediatrics and Epidemiology at Harvard Medical School and Harvard School of Public Health, where he had the pleasure of mentoring (and learning from) the talented students in his lab.
|Lee Lancashire, PhD||Cohen Veterans Bioscience|
Chief Information Officer
Lee Lancashire, PhD has over 15 years of experience in machine learning and statistics. His PhD was focused on the development of artificial neural network-based methodologies where he was involved in many of the first applications of neural nets to high dimensional datasets in bioinformatics. Prior to joining Cohen Veterans Bioscience, Lee spent over five years within the IP & Science business of Thomson Reuters where he established and led the machine learning and statistical data analysis team. Here he held global responsibility for managing and delivering analytical projects, serving the majority of the top 10 pharmaceutical companies, as well as government, academic and non-profit organizations. These projects focused on utilizing advanced machine learning approaches in the molecular profiling of disease for biomarker discovery, patient stratification and drug target identification. Lee completed his post-doctoral research in Biostatistics and Bioinformatics at the Paterson Institute for Cancer Research, a Cancer Research UK core facility. He has also worked as a bioinformatics project lead in personalized medicine and diagnostics companies CompanDX and Almac Diagnostics. He has published in over 30 key industry journals and holds several patents around the use of neural networks in the biomedical domain. In his free time Lee devotes time volunteering as a trustee for the Ichthyosis Support Group, a charity that supports individuals and families affected by a group of rare skin disorders.
ML/AI Lead, R&D Informatics, Small Molecule Discovery Informatics
No bio available
|Frederick Lee||Amazon Web Svcs|
Business Development - Life Sciences
Dr. Lee provides physician leadership in business development for an AWS New Initiative group focused on facilitating the data exchange in a regulatory compliant, ethically sound, economically sustainable, and secure cloud-native fashion. Fred's personal passion is accelerating the digitally-driven transformation of healthcare to a predictive, preventive, personalized, and participatory state.
|Sebastien Lefebvre||Alexion Pharmaceuticals Inc|
Senior Director, Data Sciences, Genomics and Bioinformatics
20 years of experience leading and building data and analytics capabilities in BioPharma. Currently at Alexion building data sciences capabilities and delivering insights in rare diseases working with BD and Commercial functions. In the prior role built the cloud-based Data Analytics & Decision Support environment for external collaboration. Past roles include Head of Global Data Office at Biogen and Head of Global R&D Information Architecture practice at AstraZeneca. Holds a MSc in Computational Chemistry and a MSc in Computer Sciences from Universitée de Montréal.
|Alexander Lex, PhD||University of Utah|
I am an Assistant Professor of Computer Science at the Scientific Computing and Imaging Institute and the School of Computing at the University of Utah. Together with Miriah Meyer, I run the Visualization Design Lab where we develop visualization methods and systems to help solve today’s scientific problems. Before joining the University of Utah, I was a lecturer and post-doctoral visualization researcher at Harvard University. I received my PhD, master’s, and undergraduate degrees from Graz University of Technology. In 2011 I was a visiting researcher at Harvard Medical School. I am the recipient of an NSF CAREER award and multiple best paper awards or honorable mentions at IEEE VIS, ACM CHI, and other conferences. I also received a best dissertation award from my alma mater. I co-founded Datavisyn, a startup company developing visual analytics solutions for the pharmaceutical industry, and the Caleydo project, an open source visualization framework for biomolecular data.
|Benjamin Li||Boehringer Ingelheim|
Global Head of ITRDM Biological Sample Production & Management, Information Technology
Zhenbin (Benjamin) Li is global head of IT RDM Biological Sample Production and Management. He is responsible for global IT needs related to biotherapeutics discovery and structure research in human pharma and animal health R&D. Benjamin holds a PhD degree from University of Georgia, and MS and BS from Nanjing University (China).
|Bin Li, PhD||Takeda Pharmaceutics|
Director, Computational Biology
Dr. Bin Li leads a translational bioinformatics team at Takeda’s global computational biology organization. His team provides computational supports on both forward and reverse translational research, on multiple therapeutic areas including oncology, GI, neuroscience, and rare diseases. They develop methods, build ML/AI predictive models, and do data-driven exploratory analyses for biomarker and patient stratification needs. His team is also responsible on method evaluation and pipeline building for various NGS platforms, including WES, RNA-seq, scRNA-seq, microbiome, and targeted panels.
|Michael Liebman, PhD||IPQ Analytics LLC|
No bio available
Senior Manager, Pfizer Digital
Yuan Lin is the Biologics Business Solution Lead in Pfizer Digital. He manages, develops, and supports Pfizer Biologics R&D informatics platforms. He is an experienced software architect/developer, business analyst, and bioinformatician. Before joining Pfizer in 2017, Yuan was a Senior Principle Business Analyst and Lead Software Engineer at Novartis, focusing on the in-house E2E biologics screening platform and leading the support of a global biologics registration platform. He led the implementation of an NGS data workflow system at GeneDX and built a comparative Genome Browser and Sequence Analysis platform that enabled the sequencing and analyzing of the first individual human genome at J Craig Venter Institute.
|Debbie Lin, PhD, MPP, MSc Eng||Boehringer Ingelheim Venture Fund USA, Inc.|
Dr. Debbie Lin is Executive Director at Boehringer Ingelheim Venture Fund in the US and leads the Fund’s North American efforts in Digital Healthcare. She joined Boehringer Ingelheim Pharmaceuticals in 2008. Within Boehringer Ingelheim Pharma, she worked across various regions and divisions. She has worked in Medical Affairs in the area of women’s health and later in Health Economics and Outcomes supporting all commercial product sales with large payers and providers accounts on the West Coast. She also led the US organization’s social entrepreneurship program in Boehringer Ingelheim’s Making More Health collaboration with Ashoka. In 2013, she transitioned to Corporate Headquarters in Germany in Corporate Strategy and Development as Director of Corporate Development. There she was responsible for BI’s global development strategy, leading BI’s global venture into stroke rehabilitation. She led multi-country teams to set up the company’s first stroke rehabilitation centers in Shanghai, China and in Lisbon, Portugal. Prior to Boehringer Ingelheim, she worked as a Public Policy Consultant for Pacific Health Policy Group supporting Medicaid Policy implementation in various states such as Vermont and West Virginia during the Clinton Administration. Her doctorate is in Pharmacogenomics and Bioinformatics from UCSF, she also has a Masters in Engineering from Stanford University and a Masters in Public Policy from UCLA. Debbie is a native Californian, she loves sunshine, being around nature and the ocean, yoga and dogs.
|Ray Liu||Takeda Pharmaceuticals|
Senior Director, Advanced Analytics and Statistical Consultation
No bio available
|Millie Liu, Mfin||First Star Ventures|
Founder, Managing Partner
Millie Liu has focused her career on helping entrepreneurs with deep technology turn their ideas into great businesses with global reach.
She was previously at APT, an enterprise data analytics startup acquired by Mastercard for $600 million where she helped Fortune 50 clients such as Walmart and P&G make better strategic decisions leveraging data. She was also the co-founder of an MIT startup working on unsupervised event detection, which later pivoted and became Infervision, an AI precision healthcare platform backed by Sequoia China. Millie is on the advisory board of MIT CSAIL (Computer Science and Artificial Intelligence Lab). She holds a Master of Finance degree from MIT and B. in Mathematics from the University of Toronto.
|Sean Liu, PhD||Takeda California Inc|
Global Head, Scientific Assets & Decision Support, Scientific Informatics
Based in San Diego, Sean Liu is leading the Scientific Assets and Decision Support group within Takeda R&D IT. His remit includes developing entity registration solutions for all modalities, assay data foundation to enable single source of truth for all assay data associated with the assets and data integration, visualization and predictive analytics to support data-driven decision making.
Director Market Access RWE Partnerships,
No bio available
|Alan Louie, PhD||IDC Health Insights|
Alan is responsible for directing the IDC Health Insights Life Sciences Practice. Dr. Louie manages a group of analysts who provide research-based advisory and consulting services for life sciences companies, technology vendors, and IT service providers across the life sciences value chain. Within the practice, Dr. Louie leads IDC Health Insights' Life Science R&D Strategy and Technology Research service with coverage of ongoing innovation and best practices in life science R&D and a further emphasis on technology and innovation in clinical development, analytics, translational research, and precision medicine. Dr. Louie brings more than 32 years of technology, product and strategy development from across the life science industry. Previously, Dr. Louie led applied biotechnology programs as Senior Manager at Arthur D. Little, Inc. In this role, he managed laboratory-based technology development programs, as well as provided content expertise to life science and healthcare strategy projects. Over his career, Dr. Louie was responsible for the development and commercialization of more than 30 products for a variety of industries, including many first-in-class product offerings.
|Nick Lynch, PhD||Curlew Research|
Founder and CTO
Nick has over 20 years’ experience in Data science & Informatics in various start-ups and biopharma. Interested in making data more accessible for better. Established Curlew Research in 2014 working with Pharma/biotech and Life Science informatics/data science companies.
|Avi Ma'ayan, PhD||Icahn School of Medicine at Mount Sinai|
Professor, Department of Pharmacological Sciences; Director, Mount Sinai Center for Bioinformatics
The research in the Ma'ayan Lab involves applying computational methods to study the complexity of regulatory networks in mammalian cells. We develop algorithms and software to study how regulatory networks control cellular processes such as differentiation, dedifferentiation, apoptosis, and proliferation. Our main focus is in developing methods that link changes in gene expression to transcriptional regulators and cell signaling pathways. To achieve this, we develop web-based bioinformatics software tools and databases that enable biologists to perform enrichment and network analyses to find new knowledge about single genes, gene sets, and drugs. Using these tools, we work closely with experimentalists on projects that utilize high-throughput profiling to understand cell regulation at the global scale. So far, we published over 160 peer-reviewed articles where several of them in top-tier journals. Over the past 12 years, about 100 trainees, including postdoctoral fellows, graduate and medical students, undergraduates, and high school students contributed to the laboratory work. The Ma’ayan Lab members participate in educational and outreach activities including delivering two MOOCs on the Coursera platform, a summer undergraduate research program, and two in-class graduate courses.
|Finlay MacLean||Elsevier Inc|
Finlay MacLean completed a Masters of Engineering in Biomedical Engineering at the University of Nottingham. He is currently working as a data scientist at Elsevier, primarily involved in drug repurposing, disease investigation and retrosynthesis prediction. He is passionate about aiding understanding of rare diseases through the use of novel computational methods.
|Thomas Madden, PhD||NCBI/NLM/NIH|
No bio available
|Ravi Madduri|| |
Scientist, Data Science and Learning, Argonne National Laboratory; Senior Scientist, University of Chicago Consortium for Advanced Science and Engineering (UChicago CASE)
No bio available
|Lara Mangravite, PhD||Sage Bionetworks|
Lara Mangravite, PhD, is President of Sage Bionetworks. This organization is focused on the development and implementation of practices for large-scale collaborative biomedical research. Our work is centered on new approaches to scientific process that use open systems to enable community-based research regarding complex biomedical problems. Previously, Dr. Mangravite served as Director of the Systems Biology research group at Sage Bionetworks where she focused on the application of collaborative approaches to advance understanding of disease biology and treatment outcomes at a systems level with the overriding goal of improving clinical care. Dr. Mangravite obtained a BS in Physics from the Pennsylvania State University and a PhD in Pharmaceutical Chemistry from the University of California, San Francisco. She completed a postdoctoral fellowship in cardiovascular pharmacogenomics at the Children’s Hospital Oakland Research Institute.
|Sylvia Marecki, PhD||EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany|
Design Analyst, Operational Design Center (ODC), Global Clinical Operations
Sylvia Marecki joined the Operational Design Center within Global Clinical Operations at EMD Serono in 2019 as a strategic thought partner driving efficiency and innovation in study planning and execution. Prior to joining EMD Serono, Sylvia led development and commercialization of data-driven analytic products and services at Citeline/Informa, Decision Resources Group, and TriNetX, empowering informed decision-making across clinical and commercial functions at all stages of the product lifecycle. She received her Doctorate in Pathology and Immunology from Boston University School of Medicine.
Scientific Solutions Lead, Engineering
Adam Marko is an IT and Life Sciences professional with over 15 years of experience meeting the analytics and infrastructure needs of researchers. He has supported scientists in the agricultural, pharmaceutical, and diagnostic spaces. At Igneous, he helps HPC customers meet their data visibility, backup, and archive needs.
|Nicola Marlin||Pharma Intelligence|
Head of AI in R&D Information Research, Senior Principal Data Scientist
Brian joined AbbVie in October of 2018 as the head of the newly formed RAIDERS team within Research & Development’s Information Research division, focused on accelerating, scaling, and amplifying the work of AbbVie’s R&D community using Artificial Intelligence technologies like machine learning, deep learning, and cognitive computing. Brian came to AbbVie after spending five years in technology consulting across many industries, and over a decade of additional experience before that working in trading and financial markets technology. During his consulting time, Brian architected the United States’ Common Securitization Platform and was a founding member of Publicis.Sapient’s AI practice. While his primary focus is AI technologies, his interests are much broader, and he has presented at multiple conferences on topics including optical networking, quantum computing, blockchain, cognitive architecture, and other emerging technology concepts that are all part of digital transformation. Brian holds a BS degree in Computer and Cognitive Science from Alma College and a MS in Computer Science from the University of Chicago. He is actively involved with technology incubator programs at Mundelein and Lake Forest High Schools, the Creative Destruction Lab at the University of Toronto’s Rotman School, and is a member of the Education Committee for District 115’s Board of Education.